Building a better model

A good percentage of ISSCR 2014 was dedicated to the development of model systems that better reflected human pathophysiology
| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00
A good percentage of ISSCR 2014 was dedicated to the development of model systems that better reflected human pathophysiology. As California Institute for Regenerative Medicine Senior Scientific Advisor Alan Trounson indicated, rodent models have not served the scientific community particularly well as they often don’t represent the heterogeneity of human disease. Furthermore, he challenged, gene knockout models have limited utility because they don’t really model diseases that involve more than one gene, which given the complexity of cellular signalling systems, for example, tends to be most conditions.
Continue reading below...
Illustration of diverse healthcare professionals interacting with digital medical data and health records on virtual screens.
WebinarsAccelerating rare disease clinical trials
Explore how a rare kidney disease trial achieved faster patient enrollment with data-informed strategies and collaborative partnerships.
Read More
Several presentations and posters therefore focused on the application of stem cell technologies to construct more accurate models of human disease using human cells, both diseased and healthy, and within a more tissue- or organ-like context.
Researchers at the BC Cancer Agency and STEMCELL Technologies, for example, described their efforts to construct an in-vitro model of the human airway by growing human bronchial epithelial cells in PneumaCult medium. This allows the cells to function at the air-liquid interface and thus mimic in vivo airway functions to understand, for example, viral infection, drug transport and bronchial disease.
Leiden University’s Christine Mummery, meanwhile, talked about the challenges of studying cardiac ion channels not only in mouse models, which offer a very different physiology from humans, but even between cultures of diseased and control human cardiomyocytes. Mummery’s approach was to develop isogenic pairs of cell lines, correcting the mutation within a patient sample to use as a control for the original patient sample. Drugs can then be tested on these pairs to determine with certainty that the results are due to the mutation and not background genetic anomalies between cell lines.
Continue reading below...
A scientist wearing gloves handles a pipette over a petri dish and a color-coded microplate in a laboratory setting.
Application NoteThe unsung tools behind analytical testing success
Learn how fundamental laboratory tools like pipettes and balances support analytical precision.
Read More
Other such efforts will be described in “Modestly modeled” in the July issue of DDNews and in a special feature on disease modeling in the November issue.

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Fluorescent-style illustration of spherical embryonic stem cells clustered together against a dark background.
Explore how emerging in vitro systems — built from primary cells, cocultures, and vascularized tissues — are improving translational research outcomes. 
3D illustration of ciliated cells, with cilia shown in blue.
Ultraprecise proteomic analysis reveals new insights into the molecular machinery of cilia.
3D illustration showing a DNA double helix encapsulated in a transparent capsule, surrounded by abstract white and orange protein-like molecular structures against a blue background.
Discover an integrated analytical approach that unites identification, purification, and stability assessment for therapeutic molecules.
Drug Discovery News December 2025 Issue
Latest IssueVolume 21 • Issue 4 • December 2025

December 2025

December 2025 Issue

Explore this issue